2026-10-12T17:25:00Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34009527 2026-09-28T05:44:42Z category_15 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217–based assessment of CSF amyloid positivity in secondary-care patients with MCI.docx María Pascual-Lucas (4805841) Leticia Sarasa (4805862) Noelia Fandos (6017480) Jorge Loscos (22407538) Judith Romero (22407541) Adrián Sánchez (22407544) Jose Terencio (15252047) Isabel Ortega-Madueño (613153) María Cruz Cárdenas (25120074) Fernando Cava-Valenciano (25120077) María José Gil-Moreno (14325825) Jordi A. Matias-Guiu (5572424) José Antonio Allué (11598287) Neuroscience ABtest-MS Alzheimer’s disease Aβ42/Aβ40 grey zone Lumipulse multimarker models p-tau217 plasma biomarkers Introduction<p>Plasma p-tau217 accurately reflects amyloid pathology, but dual-cutoff strategies leave a non-negligible grey zone requiring confirmatory testing. We evaluated whether integrating plasma Aβ measurements could reduce diagnostic uncertainty in patients with mild cognitive impairment (MCI).</p>Methods<p>Plasma p-tau217 was measured using the Lumipulse platform, and plasma Aβ40 and Aβ42 were quantified by liquid chromatography-mass spectrometry (ABtest-MS) in 186 secondary-care MCI patients. CSF Aβ42/Aβ40 defined amyloid status. Logistic regression models were compared, and dual-cutoff strategies targeting 95% predictive values were applied.</p>Results<p>p-tau217 was the strongest individual biomarker. Models incorporating plasma Aβ measures improved AUC, model fit, and reduced the grey zone from 27.4% with p-tau217 alone to 12.3%. A sequential two-step strategy restricted additional Aβ testing to p-tau217-indeterminate cases and reduced the final grey zone to 13.4%.</p>Discussion<p>Plasma Aβ measurements complement p-tau217 by reducing the indeterminate results, with the potential to improve diagnostic efficiency and streamline diagnostic workflows.</p> 2026-09-28T05:44:42Z Dataset Dataset 10.3389/fnagi.2026.1918304.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Plasma_biomarker_strategies_to_reduce_diagnostic_uncertainty_in_p-tau217_based_assessment_of_CSF_amyloid_positivity_in_secondary-care_patients_with_MCI_docx/34009527 CC BY 4.0